Listen: Pfizer’s Covid-19 vaccine data, the FDA’s Alzheimer’s quandary, and how to think like a biostatistician

How well does Pfizer’s Covid-19 vaccine work? What’s the difference between efficacy and effectiveness? And should the FDA approve Biogen’s Alzheimer’s drug?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. First, University of Florida biostatistician Natalie Dean joins us to break down Pfizer’s promising recent data on its vaccine for Covid-19. Then, following last week’s stinging setback for aducanumab, an Alzheimer’s disease treatment from Biogen, we interview to two people at the center of the story. Caleb Alexander, a Johns Hopkins epidemiologist, explains why he recommended against FDA approval for the drug, and Jeff Borghoff, who has early-onset Alzheimer’s and has received aducanumab, discusses why he believes it works.

For more on what we cover, here’s the news on Pfizer’s vaccine; here’s the latest on aducanumab; and here’s our complete coverage of the coronavirus pandemic.


We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple PodcastsStitcherGoogle Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].

Source: STAT